{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:50:06Z","timestamp":1791607806181,"version":"4.3.4"},"reference-count":52,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health","award":["R37CA251165"],"award-info":[{"award-number":["R37CA251165"]}]},{"name":"National Institutes of Health","award":["R01CA298320"],"award-info":[{"award-number":["R01CA298320"]}]},{"award":["R37CA251165"],"award-info":[{"award-number":["R37CA251165"]}],"id":[{"id":"https:\/\/ror.org\/045p44t13","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01CA298320"],"award-info":[{"award-number":["R01CA298320"]}],"id":[{"id":"https:\/\/ror.org\/045p44t13","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society Institutional Research","doi-asserted-by":"publisher","award":["IRG-19-137-20"],"award-info":[{"award-number":["IRG-19-137-20"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"award":["IRG-19-137-20"],"award-info":[{"award-number":["IRG-19-137-20"]}],"id":[{"id":"https:\/\/ror.org\/02e463172","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016947","name":"Swim Across America","doi-asserted-by":"publisher","award":["23-1579"],"award-info":[{"award-number":["23-1579"]}],"id":[{"id":"10.13039\/100016947","id-type":"DOI","asserted-by":"publisher"}]},{"award":["23-1579"],"award-info":[{"award-number":["23-1579"]}],"id":[{"id":"https:\/\/ror.org\/05d8ft347","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006942","name":"Flow Cytometry and Cell Sorting Shared Resource, Hollings Cancer Center, Medical University of South Carolina","doi-asserted-by":"publisher","award":["P30 CA138313"],"award-info":[{"award-number":["P30 CA138313"]}],"id":[{"id":"10.13039\/100006942","id-type":"DOI","asserted-by":"publisher"}]},{"award":["P30 CA138313"],"award-info":[{"award-number":["P30 CA138313"]}],"id":[{"id":"https:\/\/ror.org\/012jban78","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Pancreatic cancer (PC) is a leading cause of cancer-related death in the United States and lacks efficient therapeutic options. Serine peptidase inhibitor, clade B, member 5 (SERPINB5) is non-inhibitory toward serine proteases, yet it has diverse biological functions, including regulating cell migration, cell death, gene expression, and stress responses. Mesothelin (MSLN) is a tumor-associated antigen that is broadly overexpressed on various malignant tumor cells and plays a crucial role in promoting proliferation, invasion, and metastasis. Methods: We integrated public database analyses, cell-line screening, gene knockdown and overexpression, immunoblotting, cell viability and apoptosis assays, flow cytometry, chromatin immunoprecipitation paired with quantitative PCR (ChIP-qPCR), and chimeric antigen receptor (CAR) T-cell therapy to investigate SERPINB5 and MSLN functions, developing a novel and effective therapeutic strategy for patients with pancreatic cancer. Results: Both SERPINB5 and MSLN are highly expressed and negatively associated with the overall survival of PC patients. Our mechanistic study suggests that SERPINB5 negatively regulates the mitochondrial protein dehydrogenase\/reductase 2 (DHRS2) to promote PC cell survival; consequently, SERPINB5 depletion induces PC cell apoptosis. Of note, SERPINB5 depletion increases MSLN transcription by enhancing c-Myc binding to the MSLN promoter region, which in turn suppresses the mitochondrial protein DHRS2 and leads to resistance to apoptosis in PC cells. Our genetic ablation study shows that SERPINB5 and MSLN are critical for PC cell survival, and that depleting both proteins synergistically induces PC cell apoptosis. Gemcitabine (GEM) is a standard chemotherapy drug for PC treatment. Our study shows that SERPINB5-high PC cells display greater sensitivity to GEM than SERPINB5-low PC cells. GEM treatment increases mitochondrial DHRS2 protein expression, similar to the effect of SERPINB5 knockdown, whereas upregulated MSLN confers apoptotic resistance by decreasing DHRS2 levels. Conclusions: Our in vitro study demonstrates that sequential treatment with GEM followed by anti-MSLN chimeric antigen receptor (CAR)-T cells is an effective and promising strategy for patients with pancreatic cancer. Future studies using mouse models may validate the efficacy of this sequential treatment strategy in vivo.<\/jats:p>","DOI":"10.3390\/cancers18193242","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:16:52Z","timestamp":1791472612000},"page":"3242","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting SERPINB5 and MSLN for Pancreatic Cancer Therapy"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5651-9862","authenticated-orcid":false,"given":"Jinghui","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8510-3759","authenticated-orcid":false,"given":"Rhyston","family":"Broadhurst","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wang","sequence":"additional","affiliation":[{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA"},{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis C.","family":"Guttridge","sequence":"additional","affiliation":[{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo M. R.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA"},{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3477-8673","authenticated-orcid":false,"given":"Haizhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA"},{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-0437","authenticated-orcid":false,"given":"Xueliang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA"},{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"ref_2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and Opportunities for Pancreatic Cancer Immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"26605","DOI":"10.1038\/srep26605","article-title":"Serpin peptidase inhibitor (SERPINB5) haplotypes are associated with susceptibility to hepatocellular carcinoma","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11669","DOI":"10.1073\/pnas.93.21.11669","article-title":"Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells","volume":"93","author":"Sheng","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/0008-5472.CAN-05-3514","article-title":"Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator\/urokinase-type plasminogen activator receptor system","volume":"66","author":"Yin","year":"2006","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"34210","DOI":"10.1074\/jbc.M503523200","article-title":"Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: Identification of a novel serpin partnership","volume":"280","author":"Bailey","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_10","first-page":"812","article-title":"Expression of the tumor suppressor gene Maspin in human pancreatic cancers","volume":"7","author":"Maass","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_11","first-page":"2924","article-title":"The paradoxical expression of maspin in ovarian carcinoma","volume":"8","author":"Sood","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ijc.10500","article-title":"Expression of maspin predicts poor prognosis in breast-cancer patients","volume":"100","author":"Umekita","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8677","DOI":"10.1038\/sj.onc.1207127","article-title":"Maspin\u2014The most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer\u2014Is strongly expressed in preneoplastic bronchial lesions","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1365-2559.2003.01620.x","article-title":"Expression of maspin is up-regulated during the progression of mammary ductal carcinoma","volume":"42","author":"Umekita","year":"2003","journal-title":"Histopathology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0009-9120(01)00220-X","article-title":"Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis","volume":"34","author":"Maass","year":"2001","journal-title":"Clin. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/path.948","article-title":"Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast","volume":"195","author":"Maass","year":"2001","journal-title":"J. Pathol."},{"key":"ref_17","first-page":"1172","article-title":"Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation","volume":"8","author":"Zou","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00432-004-0571-x","article-title":"Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma","volume":"130","author":"Nakashima","year":"2004","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1158\/0008-5472.CAN-19-2578","article-title":"Cancer Cell-Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma","volume":"80","author":"Tian","year":"2020","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13046-024-03015-w","article-title":"Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET","volume":"43","author":"Xia","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/ijms.39012","article-title":"Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"17","author":"Le","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Montemagno, C., Cassim, S., Pouyssegur, J., Broisat, A., and Pages, G. (2020). From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21114067"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/hpb.12199","article-title":"Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer","volume":"16","author":"Kendrick","year":"2014","journal-title":"HPB"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"jcs210724","DOI":"10.1242\/jcs.210724","article-title":"Acute HSF1 depletion induces cellular senescence through the MDM2-p53-p21 pathway in human diploid fibroblasts","volume":"131","author":"Oda","year":"2018","journal-title":"J. Cell Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/onc.2017.383","article-title":"DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma","volume":"37","author":"Zhou","year":"2018","journal-title":"Oncogene"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41419-022-05291-w","article-title":"DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHK\u03b1 to disrupt choline metabolism","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"119846","DOI":"10.1016\/j.bbamcr.2024.119846","article-title":"DHRS2-induced SPHK1 downregulation contributes to the cell growth inhibition by Trichothecin in colorectal carcinoma","volume":"1871","author":"Liu","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13062-025-00721-z","article-title":"Synergistic anticancer effects of cabozantinib and cuproptosis induction driven by DHRS2-KAT2A-H3K27ac axis in clear cell renal cell carcinoma","volume":"21","author":"Cao","year":"2026","journal-title":"Biol. Direct"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lee, D.E., Kang, H.W., Kim, S.Y., Kim, M.J., Jeong, J.W., Hong, W.C., Fang, S., Kim, H.S., Lee, Y.S., and Kim, H.J. (2022). Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.934746"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"112219","DOI":"10.1016\/j.isci.2025.112219","article-title":"Supinoxin blocks small cell lung cancer progression by inhibiting mitochondrial respiration through DDX5","volume":"28","author":"Das","year":"2025","journal-title":"iScience"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbrc.2023.04.066","article-title":"Epigenetic regulation of DHRS2 by SUV420H2 inhibits cell apoptosis in renal cell carcinoma","volume":"663","author":"Ryu","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_34","unstructured":"Feldman, S.A., Rosenberg, S.A., and Pastan, I.H. (2016). Anti-Mesothelin Chimeric Antigen Receptors. (US20150031624A1), U.S. Patent."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-0716-3593-3_15","article-title":"Redirecting Human Conventional and Regulatory T Cells Using Chimeric Antigen Receptors","volume":"Volume 2748","author":"Zimmerman","year":"2024","journal-title":"Cancer Immunotherapy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8164","DOI":"10.1073\/pnas.1332764100","article-title":"A global transcriptional regulatory role for c-Myc in Burkitt\u2019s lymphoma cells","volume":"100","author":"Li","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1056\/NEJMp078126","article-title":"Pluripotency redux\u2014Advances in stem-cell research","volume":"357","author":"Gearhart","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41392-020-00235-2","article-title":"Regulation of cancer cell metabolism: Oncogenic MYC in the driver\u2019s seat","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.12659\/MSM.917625","article-title":"Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K\/AKT\/NF-\u03baB Pathway","volume":"25","author":"Liu","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1111\/1759-7714.15013","article-title":"SERPINB5 is a prognostic biomarker and promotes proliferation, metastasis and epithelial-mesenchymal transition (EMT) in lung adenocarcinoma","volume":"14","author":"He","year":"2023","journal-title":"Thorac. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"114055","DOI":"10.1016\/j.yexcr.2024.114055","article-title":"Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies","volume":"439","author":"Muller","year":"2024","journal-title":"Exp. Cell Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101728","DOI":"10.1016\/j.tranon.2023.101728","article-title":"STAMBPL1 promotes the progression of lung adenocarcinoma by inhibiting DHRS2 expression","volume":"35","author":"Yang","year":"2023","journal-title":"Transl. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcyt.2024.01.011","article-title":"Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity","volume":"26","author":"Chu","year":"2024","journal-title":"Cytotherapy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","volume":"395","author":"Wainberg","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/labinvest.2011.66","article-title":"Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis","volume":"91","author":"Goulet","year":"2011","journal-title":"Lab. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000236022","article-title":"Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?","volume":"77","author":"Hashimoto","year":"2009","journal-title":"Oncology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1245\/s10434-011-2110-8","article-title":"Neoadjuvant\/preoperative gemcitabine for patients with localized pancreatic cancer: A meta-analysis of prospective studies","volume":"19","author":"Andriulli","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1586\/era.12.115","article-title":"Treatment options for advanced pancreatic cancer: A review","volume":"12","author":"Warsame","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MPA.0000000000001507","article-title":"Landscape of Health-Related Quality of Life in Patients with Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review","volume":"49","author":"Macarulla","year":"2020","journal-title":"Pancreas"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","article-title":"Mesothelin-targeted CAR-T cell therapy for solid tumors","volume":"21","author":"Klampatsa","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.5114\/aoms.2019.84888","article-title":"Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors","volume":"17","author":"Zhang","year":"2021","journal-title":"Arch. Med. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhai, X., Mao, L., Wu, M., Liu, J., and Yu, S. (2023). Challenges of Anti-Mesothelin CAR-T-Cell Therapy. Cancers, 15.","DOI":"10.3390\/cancers15051357"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3242\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:17:43Z","timestamp":1791605863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":52,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193242"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193242","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]}}}